^
Association details:
| Biomarker: | EML4-ALK variant 3 + TP53 mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Patient-derived lung cancer organoids for the selection of therapeutic options in an ALK-rearranged tumor.
Published date:
05/19/2021
Excerpt:
A next-generation sequencing (NGS) panel revealed the presence of the EML4-ALK fusion variant 3a/b....A second NGS panel did not identify any new ALK resistance mutation but acquiring TP53. Treatment was switched to brigatinib with no response. Finally, fresh tumor tissue was obtained from a liver biopsy to establish PDOs and drug sensitivity to 8 compounds was tested. The In vitro results demonstrated no activity of lorlatinib but a strong response to crizotinib.
DOI:
10.1200/JCO.2021.39.15_suppl.e21014
